GPRC5A and lung cancer: The results showed that: i) none of the 20 wild-type (WT) mice developed lung cancer (0%, 0/20); ii) none of the 10 Aldh2-KO mice developed lung cancer (0%, 0/10); ii) all the 20 Gprc5a-KO (5a-KO) mice developed lung cancer (100%, 20/20); and iv) only one of the 29 Gprc5a-KO/Aldh2-KO mice (1/29) developed lung cancer (3.3%) (Fig. 1J and K).